EUROPEAN STUDY FINDS THE ABBOTT CARDIOMEMS SENSOR RESULTS IN IMPROVED QUALITY OF LIFE AND 44% REDUCTION IN HEART FAILURE HOSPITALIZATIONS

EUROPEAN STUDY FINDS THE ABBOTT CARDIOMEMS SENSOR RESULTS IN IMPROVED QUALITY OF LIFE AND 44% REDUCTION IN HEART FAILURE HOSPITALIZATIONS New data presented from an investigator-sponsored European trial found managing…

Read MoreEUROPEAN STUDY FINDS THE ABBOTT CARDIOMEMS SENSOR RESULTS IN IMPROVED QUALITY OF LIFE AND 44% REDUCTION IN HEART FAILURE HOSPITALIZATIONS

Teva to Present Data

Teva to Present Data Demonstrating UZEDY™ (risperidone) Extended-Release Injectable Suspension Significantly Prolonged Time to Impending Relapse for Adults with Schizophrenia at the American Psychiatric Association’s 2023 Annual Meeting Teva Pharmaceuticals,…

Read MoreTeva to Present Data

DUPIXENT® (DUPILUMAB) LATE-BREAKING PHASE 3 COPD RESULTS PRESENTED AT ATS AND SIMULTANEOUSLY PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE

DUPIXENT® (DUPILUMAB) LATE-BREAKING PHASE 3 COPD RESULTS PRESENTED AT ATS AND SIMULTANEOUSLY PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today presented positive Phase…

Read MoreDUPIXENT® (DUPILUMAB) LATE-BREAKING PHASE 3 COPD RESULTS PRESENTED AT ATS AND SIMULTANEOUSLY PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE

ABBOTT UNVEILS LATE-BREAKING DATA SHOWING THE WORLD’S FIRST DUAL-CHAMBER LEADLESS PACEMAKER STUDY MET ALL THREE PRIMARY ENDPOINTS

ABBOTT UNVEILS LATE-BREAKING DATA SHOWING THE WORLD’S FIRST DUAL-CHAMBER LEADLESS PACEMAKER STUDY MET ALL THREE PRIMARY ENDPOINTS Abbott (NYSE: ABT) today announced late-breaking results from the AVEIR™ dual-chamber (DR) i2i™ Investigational…

Read MoreABBOTT UNVEILS LATE-BREAKING DATA SHOWING THE WORLD’S FIRST DUAL-CHAMBER LEADLESS PACEMAKER STUDY MET ALL THREE PRIMARY ENDPOINTS

HIGH SCHOOL SCIENTISTS AND ENGINEERS WIN NEARLY $9 MILLION AT THE REGENERON INTERNATIONAL SCIENCE AND ENGINEERING FAIR 2023

HIGH SCHOOL SCIENTISTS AND ENGINEERS WIN NEARLY $9 MILLION AT THE REGENERON INTERNATIONAL SCIENCE AND ENGINEERING FAIR 2023  Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) announced that Kaitlyn Wang, 17, of San…

Read MoreHIGH SCHOOL SCIENTISTS AND ENGINEERS WIN NEARLY $9 MILLION AT THE REGENERON INTERNATIONAL SCIENCE AND ENGINEERING FAIR 2023

Roche’s BTK inhibitor fenebrutinib significantly reduced brain lesions in people with relapsing forms of multiple sclerosis

Roche’s BTK inhibitor fenebrutinib significantly reduced brain lesions in people with relapsing forms of multiple sclerosis Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive results from the Phase II…

Read MoreRoche’s BTK inhibitor fenebrutinib significantly reduced brain lesions in people with relapsing forms of multiple sclerosis